Advanced ovarian cancer patients facing treatment resistance may find renewed hope in combination immunotherapy approaches, though recent trial results suggest the path forward remains complex. The challenge lies in reactivating immune surveillance against tumors that have learned to evade the body's natural defenses through multiple sophisticated mechanisms.
Investigators tested SL-172154, a dual-action immunotherapy that simultaneously blocks CD47 "don't eat me" signals while activating CD40 pathways to enhance immune cell function. When combined with existing treatments in 86 platinum-resistant ovarian cancer patients, the compound showed a 20% response rate with pegylated liposomal doxorubicin—potentially exceeding historical expectations for this chemotherapy alone. However, combination with mirvetuximab soravtansine yielded response rates of 33% in folate receptor-high patients and 15% in those with medium-low expression, failing to improve upon mirvetuximab's established performance.
This outcome illuminates the intricate challenge of ovarian cancer immunotherapy. The tumor microenvironment creates multiple barriers: limited drug penetration into dense tumor masses, insufficient duration of target blockade, and T cell exhaustion that persists despite CD40 activation. The bispecific approach represents sophisticated thinking—targeting both macrophage activation and dendritic cell priming simultaneously—yet the results underscore how cancer's adaptive resistance mechanisms often outpace single interventions. For a disease with few treatment options after platinum resistance develops, even modest improvements warrant attention, but the findings suggest that overcoming ovarian cancer's immune evasion will likely require more comprehensive combination strategies addressing multiple resistance pathways concurrently.